PUBLICATIONS · 12860964
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2003 Sep 1
- First author
- Ozols RF
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- J Clin Oncol. 2003 Sep 1;21(17):3183-5. doi: 10.1200/JCO.2003.06.077.
- note
- Source null
- related pmid
- 12860965
- relationship
- Comment in
- citation
- J Clin Oncol. 2023 Sep 1;41(25):4077-4083. doi: 10.1200/JCO.22.02766.
- note
- Source null
- related pmid
- 37643542
- relationship
- Republished in
Authors and identifiers
- name
- Ozols RF
- type
- Author
- name
- Bundy BN
- type
- Author
- name
- Greer BE
- type
- Author
- name
- Fowler JM
- type
- Author
- name
- Clarke-Pearson D
- type
- Author
- name
- Burger RA
- type
- Author
- name
- Mannel RS
- type
- Author
- name
- DeGeest K
- type
- Author
- name
- Hartenbach EM
- type
- Author
- name
- Baergen R
- type
- Author
- name
- Gynecologic Oncology Group
- type
- CollectiveName
Complete bibliographic record and source provenance
- authors
- name
- Ozols RF
- type
- Author
- name
- Bundy BN
- type
- Author
- name
- Greer BE
- type
- Author
- name
- Fowler JM
- type
- Author
- name
- Clarke-Pearson D
- type
- Author
- name
- Burger RA
- type
- Author
- name
- Mannel RS
- type
- Author
- name
- DeGeest K
- type
- Author
- name
- Hartenbach EM
- type
- Author
- name
- Baergen R
- type
- Author
- name
- Gynecologic Oncology Group
- type
- CollectiveName
- bibliography ids
- nci-bib-ffdf17dc2272ee43da4fa7e5
- book metadata
- content sha256
- 8c7340f0ecc741ee357274986d19a79903e5f52d8d645cda72202a681c41c8c5
- document type
- citation
- dois
- 10.1200/JCO.2003.02.153
- electronic publication date
- display
- 2003 Jul 14
- precision
- day
- year
- 2003
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:12860964
- immutable id
- pubmed:12860964@8c7340f0ecc741ee357274986d19a79903e5f52d8d645cda72202a681c41c8c5
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- Source null
- issn print
- 0732-183X
- issue
- 17
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 3194-200
- volume
- 21
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- J Clin Oncol. 2003 Sep 1;21(17):3183-5. doi: 10.1200/JCO.2003.06.077.
- note
- Source null
- related pmid
- 12860965
- relationship
- Comment in
- citation
- J Clin Oncol. 2023 Sep 1;41(25):4077-4083. doi: 10.1200/JCO.22.02766.
- note
- Source null
- related pmid
- 37643542
- relationship
- Republished in
- outcomes validated
- false
- pmid
- 12860964
- provenance
- batch id
- 2d0158fe73b50bb1a4bf
- provider
- NCBI PubMed ESummary
- record sha256
- dd268e4383ee26a2c9b45b1e8eb4d1443898913e5a38511cef578575be9cf4b6
- response sha256
- d46de44782d91ef4394e88a69f82b1ee22148e8c4cf1534eb36c80479345e70e
- retrieved at
- 2026-09-09T23:45:50.935339+00:00
- publication date
- display
- 2003 Sep 1
- precision
- day
- year
- 2003
- publication types
- Clinical Trial
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Randomized Controlled Trial
- Research Support, U.S. Gov't, P.H.S.
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Preserved source evidence · Not medical advice
Triangle